Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 10:00 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 1,099 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Healthy Control Subjects Clear all

Conditions: Insomnia
Interventions: E2006 1.0 mg, E2006 2.5 mg, E2006 5.0 mg, E2006 10.0 mg, E2006 25.0 mg, E2006 50.0 mg, E2006 100 mg, E2006 200 mg, Zolpidem 10 mg, E2006 Matched Placebo or Zolpidem Matched Placebo, E2006 Matched Placebo; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 122 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 2
States / cities: New York, New York • Cincinnati, Ohio

Conditions: Healthy
Interventions: MT2004, Placebo; Drug
Lead sponsor: Xi'an Biocare Pharma Ltd.; Other
Eligibility: 18 Years to 55 Years
Enrollment: 88 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Infection, Human Immunodeficiency Virus
Interventions: GSK2838232 PIB (SDD), GSK2838232 PIB (API), Placebo, Ritonavir; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy
Interventions: ALXN1007, Placebo; Drug · Other
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 25 Years to 55 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy
Interventions: N91115, Placebo, Placebo-Day 1 only; Drug
Lead sponsor: Nivalis Therapeutics, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Lakewood, Colorado

Conditions: Diabetes
Interventions: BMS-903452, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 104 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 2
States / cities: Miramar, Florida • Austin, Texas

Conditions: Healthy
Interventions: modafinil, methylphenidate, lorazepam, placebo; Drug
Lead sponsor: Orasi Medical, Inc.; Industry
Eligibility: 18 Years to 35 Years · Male only
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Elk Grove Village, Illinois

Conditions: Local Anesthesia
Interventions: Iontophoretic Drug Delivery System with Lidocaine/Epinephrine, Iontophoretic Drug Delivery System with Epinephrine; Device
Lead sponsor: Dharma Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 2
States / cities: Anaheim, California • Overland Park, Missouri

Conditions: Healthy Volunteer, Cystic Fibrosis
Interventions: PTI-801, Placebo, PTI-808; Drug
Lead sponsor: Proteostasis Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 171 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 33
States / cities: Birmingham, Alabama • Anchorage, Alaska • Stanford, California + 28 more

Conditions: Healthy
Interventions: Meditation practice; Other
Lead sponsor: Pranic Healing Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Lyndhurst, New Jersey

Conditions: Healthy Volunteers
Interventions: TAK-935, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Depressive Disorder, Major
Interventions: SUVN-911, Placebo; Drug
Lead sponsor: Suven Life Sciences Limited; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Infections, Bacterial
Interventions: GSK1322322 Initial fit for purpose tablets, GSK1322322 over granulated tablets, GSK1322322 intended commercial tablets, Placebo tablets, 13C-GSK1322322 stable isotope powder, GSK1322322 for injection, Placebo injection; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Amyloid Cardiomyopathy, Transthyretin-Related
Interventions: AG10 oral tablet, Placebo Oral Tablet; Drug
Lead sponsor: Eidos Therapeutics, a BridgeBio company; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Healthy
Interventions: IW-6118, Matching Placebo, Naproxen Sodium; Drug
Lead sponsor: Ironwood Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 30 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Healthy Participants
Interventions: LY3009104, Placebo, moxifloxacin; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Cachexia
Interventions: GSK2881078, Placebo, Itraconazole; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 108 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Acne Vulgaris
Interventions: Tazarotene (Patch application in Challenge Phase); Drug
Lead sponsor: Stiefel, a GSK Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 59 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: St. Petersburg, Florida

Conditions: CNS
Interventions: E2006, Placebo comparator; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 2
States / cities: Culver City, California • Glendale, California

Conditions: Healthy Participants
Interventions: E2730, Placebo; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Long Beach, California

Conditions: Healthy Volunteers, Tauopathies, Alzheimer Disease
Interventions: APNmAb005, Placebo; Drug
Lead sponsor: APRINOIA Therapeutics, LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Long Beach, California

Conditions: Amount of NKTR-118 in Blood, Variation in the Heart's Electrical Cycle
Interventions: NKTR-118, moxifloxacin, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Growth Hormone Disorder, Adult Growth Hormone Deficiency, Healthy
Interventions: somatropin, placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 20 Years to 50 Years · Male only
Enrollment: 86 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2000
U.S. locations: 1
States / cities: Honolulu, Hawaii

Conditions: Altitude Edema
Interventions: Advair HFA, Placebo; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 50 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Aurora, Colorado

Search by objective public record fields.

A 2-Part Single Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2006

A SAD/MAD Study to Evaluate the Safety, Tolerability, PK and PD of MT2004

A Single Dose Pharmacokinetic (PK) and Safety Study of GSK2838232 With and Without Ritonavir (RTV) Conducted in Healthy Subjects

Study to Evaluate Safety, Tolerability, PK and PD of ALXN1007 in Healthy Subjects

MAD Study Evaluating the Safety, Tolerability, and Pharmacokinetic Effects of N91115 in Healthy Subjects

Safety Study of BMS-903452 in Healthy Subjects (Panel 1-7) & Relative Bioavailability of the Crystalline and Amorphous Forms of BMS-903452 [Panels 4, 6, 11 & 12(Part A)], and Subjects With Type 2 Diabetes Mellitus (Part B)

Acute Effect of Three Neuroactive Drugs Measured by Magnetoencephalography (MEG), Electroencephalography (EEG) and the Synchronous Neural Interaction Test

Safety and Efficacy Study of an Iontophoretic Patch Containing Lidocaine and Epinephrine for Venipuncture in Healthy Adult Volunteers

Study Assessing the Safety, Tolerability, Pharmacokinetics, Food Effect, and Drug-Drug Interactions of PTI-801 in Healthy Volunteers, and Safety, Tolerability, and Pharmacokinetics of PTI-801 in Subjects With Cystic Fibrosis

Changes in Microbiota in Healthy Subjects Before and After Meditation Practices in a Controlled Environment

Safety, Tolerability, and Pharmacokinetics of Escalating Single Doses of TAK-935

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-911 in Healthy Subjects

A Three-part Study to Determine the Safety, Tolerability and Pharmacokinetics of GSK1322322 in Healthy Volunteers and Healthy Male Japanese Subjects

Single and Multiple Ascending Dose Study Assessing the Safety, Tolerability, PK and PD of AG10

Study to Evaluate Efficacy and Safety of IW-6118 in Patients Undergoing Third Molar Extraction

A Study of LY3009104 in Healthy Participants

Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic Study of GSK2881078 and Study to Evaluate the Effect of CYP3A4 Inhibition on PK of GSK2881078

A Study to Evaluate the Potential of Tazarotene Foam to Cause an Allergic Reaction When Applied to the Skin and Exposed to Light on Healthy Volunteers.

2-Part Multiple Ascending Dose Study for Safety and Pharmacokinetics in Healthy and Elderly Subjects

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of E2730 in Healthy Participants

A First-in-Human Study to Assess Single Doses of APNmAb005 in Healthy Participants

A Placebo-controlled Four Way Crossover Study to Asses the Effect of a Single Oral Dose of NKTR-118 on QTc Interval in Healthy Male Subjects

A Single Dose Trial in Healthy Caucasians and Japanese Subjects Investigating the Pharmacokinetics of Somatropin

Advair HFA in Healthy and HAPE Predisposed Subjects